CORRESP Filing
CDT Equity Inc.
Date: April 28, 2025 · CIK: 0001896212 · Accession: 0001641172-25-006420
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286684
Letter
Conduit Pharmaceuticals Inc.
Tamiami Trail North, Suite 200
Naples, Florida 34103
(648) 491-9132
April 28, 2025
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Conduit Pharmaceuticals Inc. (the " Company ")
Registration Statement on Form S-3 (File No. 333-286684) (the " Registration Statement ")
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended , the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on April 30, 2025, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time.
If you have any questions regarding this request, please contact our outside counsel, Todd Mason of Thompson Hine LLP, by telephone at (212) 908-3946 or via email at Todd.Mason@ThompsonHine.com. Please also call Todd Mason as soon as the Company's Registration Statement has been declared effective. Thank you for your attention to this matter.
Sincerely,
CONDUIT
PHARMACEUTICALS Inc.
Show Raw Text
CORRESP 1 filename1.htm Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 (648) 491-9132 April 28, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Conduit Pharmaceuticals Inc. (the " Company ") Registration Statement on Form S-3 (File No. 333-286684) (the " Registration Statement ") Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended , the Company hereby requests that the U.S. Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement to become effective on April 30, 2025, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable, unless the Company notifies you otherwise prior to such time. If you have any questions regarding this request, please contact our outside counsel, Todd Mason of Thompson Hine LLP, by telephone at (212) 908-3946 or via email at Todd.Mason@ThompsonHine.com. Please also call Todd Mason as soon as the Company's Registration Statement has been declared effective. Thank you for your attention to this matter. Sincerely, CONDUIT PHARMACEUTICALS Inc. By: /s/ Andrew Regan Name: Andrew Regan Title: Chief Executive Officer cc: Todd Mason, Thompson Hine LLP